Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Aldoxorubicin | INNO-206|Doxorubicin-EMCH | Chemotherapy - Anthracycline 13 | Aldoxorubicin (Doxorubicin-EMCH) is a derivative prodrug of doxorubicin that is converted to free doxorubicin within the acidic environment within tumors, and once converted, doxorubicin intercalates DNA, inhibits DNA synthesis and induces apoptosis (PMID: 30936721). | |
Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
Estramustine | Emcyt | Estramustin Sodium Phosphate | ||
Ketoconazole | Nizoral | Xolegel|KCZ | Ketoconazole is an anti-fungal agent that has been demonstrated to inhibit CYP17, resulting in decreased androgen production (PMID: 21092758). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02560051 | Phase II | Degarelix Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole | Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer | Terminated | USA | 0 |